CASBF Stock - CanSino Biologics Inc.
Unlock GoAI Insights for CASBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $824.88M | $345.18M | $1.03B | $4.30B | $24.89M |
| Gross Profit | $580.45M | $-876,019,000 | $-186,607,000 | $3.00B | $4.74M |
| Gross Margin | 70.4% | -253.8% | -18.1% | 69.8% | 19.0% |
| Operating Income | $-403,390,000 | $-2,035,182,000 | $-1,368,742,000 | $1.94B | $-397,818,000 |
| Net Income | $-378,884,000 | $-1,482,732,000 | $-909,431,000 | $1.91B | $-396,638,000 |
| Net Margin | -45.9% | -429.6% | -88.2% | 44.5% | -1593.6% |
| EPS | $-1.53 | $-6.01 | $-3.69 | $7.74 | $-1.60 |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
CASBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 27, 2025 | $-0.00 | $0.00 | +443.1% | ✓ BEAT |
Q3 2025 | Aug 20, 2025 | $-0.01 | $-0.00 | +92.1% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $-0.00 | $-0.01 | -3335.0% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | $-0.02 | $-0.09 | -324.9% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $-0.05 | $0.00 | +103.5% | ✓ BEAT |
Q3 2024 | Aug 29, 2024 | $-0.05 | $-0.03 | +39.8% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $-0.05 | $-0.10 | -110.9% | ✗ MISS |
Q1 2024 | Feb 21, 2024 | $-0.20 | $-0.28 | -40.5% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.03 | $-0.08 | -172.0% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-0.39 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.08 | — | — |
Q1 2023 | Feb 27, 2023 | $0.72 | $-1.78 | -347.2% | ✗ MISS |
Q4 2022 | Oct 28, 2022 | $0.84 | $-0.28 | -132.8% | ✗ MISS |
Q3 2022 | Aug 26, 2022 | $0.73 | $-0.07 | -109.0% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.73 | $0.08 | -89.4% | ✗ MISS |
Q1 2022 | Feb 25, 2022 | $1.92 | $2.31 | +20.3% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $2.87 | $1.60 | -44.3% | ✗ MISS |
Q3 2021 | Aug 27, 2021 | $7.04 | $3.85 | -45.3% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | — | $-0.06 | — | — |
Q1 2021 | Feb 25, 2021 | — | $-0.14 | — | — |
Latest News
Frequently Asked Questions about CASBF
What is CASBF's current stock price?
What is the analyst price target for CASBF?
What sector is CanSino Biologics Inc. in?
What is CASBF's market cap?
Does CASBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CASBF for comparison